About

Company Overview

Alyra Biotech is a biopharma company headquartered in Adelaide, Australia.
Our mission is to develop intrauterine technologies to reduce pelvic pain and pain-related symptoms in women.
Alyra Biotech’s patented, dual drug reservoir, immune-modulating intrauterine Alyra Device has been successfully trialled in a Phase 1 study of 12 women, with a further 90 women to trial the device in 2025.
We use a generic (repurposed) drug with known long term safety data to turn down excess Toll-Like Receptor 4-mediated immune inflammation in the uterus. We modulate the Uterus-Brain Neuroimmune Axis to reduce pain and pain-related symptoms.
This targeted approach uses the body’s own immune system, rather than drug levels in the circulation, to manage symptoms. Drug levels in the circulation are very low with minimal potential to cause drug side effects or drug-drug interactions.
Our target medical conditions include pelvic pain, endometriosis-related pain, irritable bowel syndrome, painful bladder syndrome, headache, fatigue, and premenstrual syndrome.

Building on 20 years of multi-disciplinary clinical and research experience, Gynecologist and Pain Physician, Dr Susan Evans, founded Alyra Biotech in 2017 to address the need for novel products to treat pelvic pain in women. Pelvic pain affects between 15% and 25% of women in our community and is a large area of global unmet human need.
Throughout this process, it is the needs and wishes of women that have guided Alyra Biotech’s philosophy. We have close ties with consumer groups including the Pelvic Pain Foundation of Australia. Our team listens to and addresses the priorities of women with pain, considers the needs of clinicians, utilizes international expertise, undertakes laboratory-based scientific research, provides novel options and values the feedback of trial participants.
We recognize that young women expect effective treatments for their pelvic pain or menstrual cycle-related symptoms that are effective and easy-to-use, with few adverse effects and minimal interruption to their natural hormonal cycle.

The prevention of immune system activation within the uterus and brain offers a ‘Holy Grail’ opportunity for the prevention of female chronic pain.
Our products offer a new life trajectory for young women, by reducing excess immune activation and preventing the transition from dysmenorrhea to chronic pelvic pain.
Glial activation in the central nervous system has been associated with a wide range of symptoms and conditions. For this reason, our products have potential benefits for a wide range of additional medical conditions that involve sex-specific inflammatory mechanisms.
Alyra Biotech is a recipient of a Brandon BioCatalyst CUREator Grant funded by Australia’s Medical Research Future Fund following extensive due diligence.

Parker MA, Sneddon AE, Arbon P. The Menstrual disorder of teenagers (MDOT) study: determining typical menstrual patterns and menstrual disturbance in a large population-based study of Australian teenagers. BJOG. 2010 Jan;117(2):185-92.
Bashir et al. Endometriosis leads to central nervous system-wide glial activation in a mouse model of endometriosis. J Neuroinflammation. 2023.